Core Insights - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [3] Group 1: Company Announcement - Dianthus Therapeutics announced a conference call and webcast to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [1] - The conference call is scheduled for March 9, 2026, at 8:00 a.m. ET [1] Group 2: Conference Call Details - Participants can register for the live conference call by phone and should pre-register to receive the dial-in number and personal PIN [2] - The live webcast will be accessible via the Investors section of the Dianthus Therapeutics website, with a replay available after the call [2]